EPH140 Safety of PDE-5 Inhibitors for Erectile Dysfunction: Descriptive and Disproportionality Analyses of the FDA Adverse Event Reporting System (FAERS) Database from 2010 to 2022

Abstract

Phosphodiesterase type 5 (PDE-5) inhibitors are often used as a first-line therapy for erectile dysfunction (ED). This study identifies characteristics of adverse events (AEs) and any potential safety signals associated with PDE-5 inhibitors used for ED from a post-marketing safety surveillance program.